Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Key Highlights
- ➤Q3 revenue $209.3 million, up 11% reported and 12.5% organically
- ➤FY26 revenue guidance raised to $844-$852 million, 14.5%-15.5% growth
- ➤Adjusted EPS $0.53, up from $0.46 year over year
- ➤BioLife acquisition completed, expanding Repligen’s cell therapy consumables platform
- ➤GAAP Q3 loss per share $0.68, versus $0.26 EPS last year
Expert Statements
Olivier Loeillot, President and Chief Executive Officer of Repligen
“We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”
Olivier Loeillot, President and Chief Executive Officer of Repligen
“The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”
* Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic * Closed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market * Raising FY26 revenue guidance to $844-$852 million which represents reported revenue growth of 14.5% - 15.5% WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026. The Company is also providing updated financial guidance for the full year 2026.
Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”
Get started
Create a free account to read the full story.